AU2011269000C1 - Insulin derivatives containing additional disulfide bonds - Google Patents

Insulin derivatives containing additional disulfide bonds Download PDF

Info

Publication number
AU2011269000C1
AU2011269000C1 AU2011269000A AU2011269000A AU2011269000C1 AU 2011269000 C1 AU2011269000 C1 AU 2011269000C1 AU 2011269000 A AU2011269000 A AU 2011269000A AU 2011269000 A AU2011269000 A AU 2011269000A AU 2011269000 C1 AU2011269000 C1 AU 2011269000C1
Authority
AU
Australia
Prior art keywords
insulin
human insulin
desb30 human
gglu
oeg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011269000A
Other languages
English (en)
Other versions
AU2011269000B2 (en
AU2011269000A1 (en
Inventor
Frantisek Hubalek
Thomas Borglum Kjeldsen
Svend Ludvigsen
Peter Madsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU2011269000A1 publication Critical patent/AU2011269000A1/en
Publication of AU2011269000B2 publication Critical patent/AU2011269000B2/en
Application granted granted Critical
Publication of AU2011269000C1 publication Critical patent/AU2011269000C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2011269000A 2010-06-23 2011-06-21 Insulin derivatives containing additional disulfide bonds Ceased AU2011269000C1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP10167046 2010-06-23
EP10167046.1 2010-06-23
EP10167033 2010-06-23
EP10167033.9 2010-06-23
US35915010P 2010-06-28 2010-06-28
US61/359,150 2010-06-28
US35950010P 2010-06-29 2010-06-29
US61/359,500 2010-06-29
PCT/EP2011/060383 WO2011161125A1 (en) 2010-06-23 2011-06-21 Insulin derivatives containing additional disulfide bonds

Publications (3)

Publication Number Publication Date
AU2011269000A1 AU2011269000A1 (en) 2012-12-13
AU2011269000B2 AU2011269000B2 (en) 2015-04-23
AU2011269000C1 true AU2011269000C1 (en) 2015-10-08

Family

ID=44508482

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011269000A Ceased AU2011269000C1 (en) 2010-06-23 2011-06-21 Insulin derivatives containing additional disulfide bonds

Country Status (13)

Country Link
US (2) US8853155B2 (enExample)
EP (1) EP2585485A1 (enExample)
JP (1) JP5931857B2 (enExample)
KR (1) KR20130036290A (enExample)
CN (2) CN104693302A (enExample)
AU (1) AU2011269000C1 (enExample)
BR (1) BR112012033107A2 (enExample)
CA (1) CA2802510A1 (enExample)
IL (1) IL223288A0 (enExample)
MX (1) MX337549B (enExample)
RU (1) RU2598273C2 (enExample)
WO (1) WO2011161125A1 (enExample)
ZA (1) ZA201209345B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010009850A (es) 2008-03-18 2010-09-30 Novo Nordisk As Analogos de insulina acilados y etabilizados contra proteasas.
EP2686003A2 (en) * 2011-03-15 2014-01-22 Novo Nordisk A/S Human insulin analogues and derivatives comprising cysteine substitutions
JP2015502971A (ja) * 2011-12-21 2015-01-29 ノヴォ ノルディスク アー／エス Ｎ末端修飾インスリン誘導体
EP2836508B1 (en) 2012-04-11 2016-06-29 Novo Nordisk A/S Insulin formulations
WO2014009316A1 (en) 2012-07-09 2014-01-16 Novo Nordisk A/S Novel use of insulin derivatives
KR20160065126A (ko) 2013-10-07 2016-06-08 노보 노르디스크 에이/에스 인슐린 유사체의 신규한 유도체
AR099569A1 (es) * 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
JP6737793B2 (ja) * 2015-01-29 2020-08-12 ノヴォ ノルディスク アー／エス 錠剤コアとポリビニルアルコールコーティングとを含む経口インスリン投与のための医薬組成物
KR20180097517A (ko) * 2015-12-23 2018-08-31 케이스 웨스턴 리저브 유니버시티 매우 안정된 인슐린 유사체의 중합체 용융물 내 캡슐화
CN107436311B (zh) * 2016-05-25 2021-11-19 正大天晴药业集团股份有限公司 一种鉴别胰岛素单体或胰岛素多聚体的方法
AU2017378102B2 (en) 2016-12-16 2022-10-13 Novo Nordisk A/S Insulin containing pharmaceutical compositions
KR102666154B1 (ko) 2018-08-08 2024-05-20 주식회사 대웅제약 지속형 인슐린 아날로그 및 그 복합체
CN113121649B (zh) * 2019-12-26 2022-10-04 李瑛� 一种新型两亲性蛋白、其制备方法及用途
CN116789801B (zh) * 2023-08-21 2023-11-14 南京赛诺生物技术有限公司 新型胰岛素衍生物及其用途
WO2025104600A1 (en) * 2023-11-15 2025-05-22 Ambio, Inc. Insulin analogs for the treatment of human metabolic disorder and disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000321A1 (en) * 1990-06-28 1992-01-09 Novo Nordisk A/S Novel, protracted insulin analogues

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE50892B1 (en) 1980-02-11 1986-08-06 Novo Industri As Process for preparing insulin esters
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK105489D0 (da) 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
ZA954983B (en) 1994-06-17 1996-02-14 Novo Nordisk As N-terminally extended proteins expressed in yeast
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
EP1039920A4 (en) * 1997-10-24 2003-05-28 Lilly Co Eli INSULIN ANALOGS ACYLATED BY FATTY ACID
PL351326A1 (en) 1999-03-17 2003-04-07 Novo Nordisk As Method for acylating peptides and novel acylating agents
RU2283846C2 (ru) 1999-12-29 2006-09-20 Ново Нордиск А/С Предшественник инсулина, способ его получения и применение
MXPA05003002A (es) 2002-09-25 2005-06-22 Novo Nordisk As Metodo para producir peptidos acilados.
AU2003903124A0 (en) * 2003-06-20 2003-07-10 Mark Del Borgo Analogues of heteromeric proteins
JP4463814B2 (ja) 2003-08-05 2010-05-19 ノボ ノルディスク アクティーゼルスカブ 新規のインスリン誘導体
JP5697831B2 (ja) 2003-12-03 2015-04-08 ノヴォ ノルディスク アー／エス 単鎖インシュリン
WO2006008238A1 (en) 2004-07-16 2006-01-26 Novo Nordisk A/S Method for selective acylation
US8343914B2 (en) * 2006-01-06 2013-01-01 Case Western Reserve University Fibrillation resistant proteins
WO2007096332A1 (en) 2006-02-21 2007-08-30 Novo Nordisk A/S Single-chain insulin analogues and pharmaceutical formulations thereof
WO2007135117A2 (en) * 2006-05-24 2007-11-29 Novo Nordisk A/S Soluble, stable insulin-containing formulations
RU2524150C2 (ru) * 2006-09-22 2014-07-27 Ново Нордиск А/С Аналоги инсулина, устойчивые к протеазам
ES2554773T3 (es) 2006-10-04 2015-12-23 Case Western Reserve University Insulina y análogos de la insulina resistentes a la fibrilación
WO2009022013A1 (en) * 2007-08-15 2009-02-19 Novo Nordisk A/S Insulin analogues with an acyl and aklylene glycol moiety
KR20100111682A (ko) 2008-01-09 2010-10-15 사노피-아벤티스 도이칠란트 게엠베하 극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
ES2618073T3 (es) 2008-03-14 2017-06-20 Novo Nordisk A/S Análogos de insulina estabilizados frente a proteasas
MX2010009850A (es) 2008-03-18 2010-09-30 Novo Nordisk As Analogos de insulina acilados y etabilizados contra proteasas.
CN106317164A (zh) 2008-09-12 2017-01-11 诺沃—诺迪斯克有限公司 酰化肽或蛋白的方法
EP2376531A1 (en) 2008-12-09 2011-10-19 Novo Nordisk A/S Novel insulin analogues
US20120184488A1 (en) 2009-09-01 2012-07-19 Case Western Reserve University Insulin analogues of enhanced receptor-binding specificity
CN102947331B (zh) 2010-06-23 2016-08-03 诺沃—诺迪斯克有限公司 包含额外的二硫键的胰岛素类似物
WO2011161083A1 (en) 2010-06-23 2011-12-29 Novo Nordisk A/S Human insulin containing additional disulfide bonds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000321A1 (en) * 1990-06-28 1992-01-09 Novo Nordisk A/S Novel, protracted insulin analogues

Also Published As

Publication number Publication date
AU2011269000B2 (en) 2015-04-23
ZA201209345B (en) 2013-08-28
BR112012033107A2 (pt) 2016-10-11
US20130157938A1 (en) 2013-06-20
JP5931857B2 (ja) 2016-06-08
EP2585485A1 (en) 2013-05-01
CA2802510A1 (en) 2011-12-29
MX2012014641A (es) 2013-02-07
US8853155B2 (en) 2014-10-07
RU2598273C2 (ru) 2016-09-20
IL223288A0 (en) 2013-02-03
WO2011161125A1 (en) 2011-12-29
KR20130036290A (ko) 2013-04-11
US20140371140A1 (en) 2014-12-18
CN102985440B (zh) 2016-10-26
AU2011269000A1 (en) 2012-12-13
CN104693302A (zh) 2015-06-10
CN102985440A (zh) 2013-03-20
RU2012157683A (ru) 2014-07-27
MX337549B (es) 2016-03-10
JP2013530974A (ja) 2013-08-01
US9512195B2 (en) 2016-12-06

Similar Documents

Publication Publication Date Title
AU2011269000C1 (en) Insulin derivatives containing additional disulfide bonds
US8815798B2 (en) Insulin analogues containing additional disulfide bonds
DK3055325T3 (en) New derivative of an insulin analogue
KR20110061552A (ko) 할로겐 안정화된 인슐린
US20140315797A1 (en) Novel N-Terminally Modified Insulin Derivatives
JP2018500385A (ja) コノトキシンペプチドの修飾および使用
US20140357838A1 (en) N-Terminally Modified Insulin Derivatives
US8883722B2 (en) Human insulin containing additional disulfide bonds

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 25 JUN 2015 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 25 JUN 2015

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired